Natco Pharma Ltd. reported consolidated total revenue of Rs590.70 crore for Q3FY22 against Rs386 crore for the previous corresponding quarter, up by 53.03% yoy.
The company reported an EBITDA of Rs132 crore for the quarter ended December 2021, as compared to Rs113.30 crore for the previous corresponding quarter, registering a growth of 16.50% yoy.
PAT after considering minority interest was Rs80.40 crore for the current quarter against Rs62.70 crore for the previous corresponding quarter, up by 28.23% yoy.
EBITDA margin for the quarter narrowed to 22.3% for the quarter ended December 2021, against 29.40% for the previous corresponding quarter. PAT margin was 13.6% for Q3FY22 against 16.2% for Q3FY21.
Natco’s total revenue consists of API Revenue at Rs61.70 crore, Formulation revenue at Rs483.40 crore, and revenue from crop health sciences was Rs0.30 crore, and other operating & non-operating incomes stood at Rs45.30 crore.
At around 12.52 PM, Natco Pharma was trading marginally higher at Rs884.20 against its previous closing price of Rs882.50. It touched day’s high of Rs885.75 and low of Rs876 so far.
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.